Jin Ng Zhang, Gopinath Subash C B
School of Bioprocess Engineering, Universiti Malaysia Perlis, 02600 Arau, Perlis, Malaysia.
School of Bioprocess Engineering, Universiti Malaysia Perlis, 02600 Arau, Perlis, Malaysia; Institute of Nano Electronic Engineering, Universiti Malaysia Perlis, 01000 Kangar, Perlis, Malaysia.
Biomed Pharmacother. 2016 Dec;84:356-365. doi: 10.1016/j.biopha.2016.09.057. Epub 2016 Sep 23.
Hemostasis initiates a wound healing process and stops bleeding of blood within a damaged tissue, an important process in human and animal systems. However, this process needs to revert temporarily during surgery and analyze the clotting mechanism. In the past decade, heparin has been used widely as an anticoagulant in surgery to prevent unwanted blood clotting as it is not expensive, not difficult to control, lack of suitable replacement as well as less harmful to the human. However, heparin has several disadvantages, which include thrombocytopenia and non-specific plasma binding. Moreover, using heparin it may lead dysfunction and platelet aggregation. In this overview, potential clotting factors and anticoagulants are reviewed and special focus was given to get more insights.
止血启动伤口愈合过程并阻止受损组织内的血液出血,这在人类和动物系统中是一个重要过程。然而,在手术过程中这个过程需要暂时逆转并分析凝血机制。在过去十年中,肝素作为抗凝剂在手术中被广泛使用,以防止不必要的血液凝固,因为它价格不贵、易于控制、缺乏合适的替代品且对人体危害较小。然而,肝素存在几个缺点,包括血小板减少症和非特异性血浆结合。此外,使用肝素可能会导致功能障碍和血小板聚集。在本综述中,对潜在的凝血因子和抗凝剂进行了综述,并特别关注以获得更多见解。